Human gut microbiome: Therapeutic opportunities for metabolic syndrome—Hype or hope?
Endocrinology, Diabetes & Metabolism · 2024-01 · 7 (1)
DOI: 10.1002/edm2.436 ↗At a glance
Übersichtsarbeit in Endocrinology, Diabetes & Metabolism, published online on 2023-09-28. Written by Angela Horvath and 4 co-authors. Institution: Medical University of Graz, Graz, Austria. Major MEDLINE topics: Gastrointestinal Microbiome, Metabolic Syndrome, Microbiota, Metabolic Diseases. Cited 26 times so far (Crossref); 176 references. The full text is freely available (open access, CC BY 4.0). Funded by: Austrian Science Fund FWF, Austrian Science Fund.
Abstract (original language)
Shifts in gut microbiome composition and metabolic disorders are associated with one another. Clinical studies and experimental data suggest a causal relationship, making the gut microbiome an attractive therapeutic goal. Diet, intake of probiotics or prebiotics and faecal microbiome transplantation (FMT) are methods to alter a person's microbiome composition. Although FMT may allow establishing a proof of concept to use microbiome modulation to treat metabolic disorders, studies show mixed results regarding the effects on metabolic parameters as well as on the composition of the microbiome. This review summarizes the current knowledge on diet, probiotics, prebiotics and FMT to treat metabolic diseases, focusing on studies that also report alterations in microbiome composition. Furthermore, clinical trial results on the effects of common drugs used to treat metabolic diseases are synopsized to highlight the bidirectional relationship between the microbiome and metabolic diseases. In conclusion, there is clear evidence that microbiome modulation has the potential to influence metabolic diseases; however, it is not possible to distinguish which intervention is the most successful. In addition, a clear commitment from all stakeholders is necessary to move forward in the direction of developing targeted interventions for microbiome modulation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Medical University of Graz, Graz, Austria.
- Center for Biomarker Research in Medicine (CBmed), Graz, Austria.
- Life Sciences Centre, Vilnius University, Vilnius, Lithuania.
ORCID profiles: Vanessa Stadlbauer
Funding
- Austrian Science Fund FWF
- Austrian Science Fund
Cite
APA
Horvath, A., Zukauskaite, K., Hazia, O., Balazs, I., & Stadlbauer, V. (2024). Human gut microbiome: Therapeutic opportunities for metabolic syndrome—Hype or hope?. Endocrinology, Diabetes & Metabolism, 7(1). https://doi.org/10.1002/edm2.436
Vancouver
Horvath A, Zukauskaite K, Hazia O, Balazs I, Stadlbauer V. Human gut microbiome: Therapeutic opportunities for metabolic syndrome—Hype or hope?. Endocrinology, Diabetes & Metabolism. 2024;7(1). doi:10.1002/edm2.436
BibTeX
@article{Horvath2024,
author = {Horvath, Angela and Zukauskaite, Kristina and Hazia, Olha and Balazs, Irina and Stadlbauer, Vanessa},
title = {Human gut microbiome: Therapeutic opportunities for metabolic syndrome—Hype or hope?},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2024},
volume = {7},
number = {1},
doi = {10.1002/edm2.436}
}
EUVIMED